Minoxidil
K-channel activator, topical or oral (Rogaine, Loniten + LDOM). Androgenetic alopecia treatment since 1988 – two administration routes with very different systemic exposure profiles.
The links above are labelled third-party affiliate links. MolekulaX does not sell and does not verify product quality.
Related comparisons
Finasteride vs MinoxidilWHAT IS MINOXIDIL?
Detailed overview
Minoxidil was originally developed as an oral antihypertensive (Loniten, 1979). Hypertrichosis observed as a side effect led to topical formulations for alopecia (Upjohn Rogaine 2% 1988, 5% 1996). The two routes have fundamentally different pharmacokinetic profiles: topical systemic absorption is <2%, so blood-pressure impact is minimal; oral LDOM (0.25–5 mg/day) provides systemic exposure, more effective than topical (Perera & Sinclair 2017 PMID 29167734), but requires cardiovascular monitoring.
ATC code
D11AX01 (topical); oral C02DC01
Prescription
Over-the-counter (OTC) topical; oral prescription only (Rx)
Mechanism
ATP-sensitive K-channel opener (vasodilator); activated by SULT1A1
Half-life
22 h (topical); 3-4 h (oral)
Onset
2-4 months (visible hair regrowth)
Data console
Lab data
Safety
Side effects, stop signs, contraindications
Side effects · 7
- Fluid retention and edema (oral): sodium and water retention, ankle and facial swelling, weight gain; often requires a co-administered diuretic (e.g. furosemide).
- Reflex tachycardia and palpitations: vasodilation triggers a compensatory rise in heart rate (+10–20 bpm), which can worsen angina with the oral form.
- Hypotension and postural hypotension (oral): systemic blood-pressure drop, dizziness, light-headedness; additive effect with antihypertensives.
- Hypertrichosis and hirsutism: unwanted body and facial hair growth, more pronounced with systemic (oral) exposure; the most common reason women discontinue treatment.
- Initial paradoxical shedding (telogen effluvium): a transient increase in hair loss in the first 2–8 weeks before regrowth begins, not a treatment failure.
- Local scalp reactions (topical): itching, flaking, dryness, redness; often propylene-glycol-vehicle contact dermatitis (the foam formulation is PG-free).
- Unwanted facial hair from runoff (topical): solution reaching the forehead, temples or ears can cause local hair growth if it is not allowed to dry properly.
Contraindications · 2
- Active scalp dermatitis or infection
- Contact allergy to propylene glycol (foam formulation is PG-free alternative)
Related Pharmaceuticals
Same therapeutic category
Studies
Related research and clinical findings
Treatment of chronic telogen effluvium with oral minoxidil: A retrospective study
Perera E, Sinclair R.
Topical minoxidil for androgenetic alopecia: meta-analysis
Suchonwanit P, Thammarucha S, Leerunyakul K.
Very-low-dose oral minoxidil in male androgenetic alopecia: A study with quantitative trichoscopic documentation
Pirmez R, Salas-Callo CI.
A double-blind, randomized clinical trial of 5% minoxidil vs 2% in men
Olsen EA, Dunlap FE, Funicella T, et al.
Safety of low-dose oral minoxidil for hair loss: A multicenter study of 1404 patients
Vañó-Galván S, Pirmez R, Hermosa-Gelbard A, et al.
Telegram
Have a question about Minoxidil?
Educational drug info from official sources (PubMed, FDA, EMA). Does NOT replace medical consultation or the SmPC. Talk to your doctor!
Personalized consultation
Want a detailed conversation tailored to your data?
Fill out the prep intake form (your goals, training and health data), and the advisor prepares from it to give genuinely personalized guidance.
Fill out the form~5–7 min · prep questionnaire · confidential · GDPR-compliant
The information here is for educational and scientific purposes only. Medication use requires medical consultation and a prescription. The indications, dose ranges, and side effects listed here do NOT replace the official Summary of Product Characteristics (SmPC) or consultation with a physician. Do not start or stop any medication on your own. In an emergency, call your local emergency number.